Company intelligence / Profile preview

URGO Group

Ownership: Private
Employees: ~3600
Development stage: Commercial

Overview

URGO Group is a leading French healthcare group specializing in advanced wound care and consumer health. Its medical division offers innovative evidence-based dressings and solutions for chronic and acute wounds. The company has invested heavily in R&D—most notably launching the Genesis laboratory to develop artificial skin for severe wounds. Its portfolio includes commercialized products such as lipido-colloid hydrogel dressings and hypochlorous acid-based cleansing solutions.

Therapeutic areas: Dermatology
Modalities: DeviceHydrogel-based drug delivery therapy
Industry: Consumable Medical Devices

Drug pipeline

1 asset

MEDIFLY

Commercial

Indications: Chronic wounds

Partnerships

Acquired Realm Therapeutics assets

Beyond the preview

Go deeper on URGO Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on URGO Group.

Explore the full profile